GI 108
Alternative Names: GI-108Latest Information Update: 28 Nov 2023
At a glance
- Originator GI Innovation
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action 5-nucleotidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 28 Nov 2023 GI Innovation plans to submit IND application in the first half of next year (GI Innovation website, November 2023)
- 28 Nov 2023 GI Innovation plans clinical trial for cancer (GI Innovation website, November 2023)
- 11 Oct 2023 Preclinical trials in Cancer in South Korea (Parenteral) (GI Innovation pipeline; October 2023)